Aequus Pharmaceuticals Inc. (AQS.V)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 5499.00 CAD | -99.52% |
| 2022 | 1.14 Million CAD | -57.37% |
| 2021 | 2.68 Million CAD | 3.71% |
| 2020 | 2.59 Million CAD | 58.81% |
| 2019 | 1.63 Million CAD | 15.76% |
| 2018 | 1.41 Million CAD | 23.77% |
| 2017 | 1.13 Million CAD | 62.4% |
| 2016 | 701.63 Thousand CAD | 908.54% |
| 2015 | -86.77 Thousand CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1882.00 CAD | 13.85% |
| 2024 Q2 | 74.85 Thousand CAD | 3877.21% |
| 2023 Q1 | 18.51 Thousand CAD | -93.66% |
| 2023 Q2 | 17.18 Thousand CAD | -7.2% |
| 2023 Q4 | 1653.00 CAD | 105.19% |
| 2023 Q3 | -31.84 Thousand CAD | -285.37% |
| 2023 FY | 5499.00 CAD | -99.52% |
| 2022 Q4 | 291.76 Thousand CAD | -9.76% |
| 2022 Q2 | 333.83 Thousand CAD | 14.13% |
| 2022 Q1 | 292.49 Thousand CAD | -65.66% |
| 2022 FY | 1.14 Million CAD | -57.37% |
| 2022 Q3 | 323.3 Thousand CAD | -3.15% |
| 2021 Q2 | 646.56 Thousand CAD | 32.17% |
| 2021 Q4 | 851.65 Thousand CAD | 21.41% |
| 2021 FY | 2.68 Million CAD | 3.71% |
| 2021 Q1 | 489.2 Thousand CAD | -42.53% |
| 2021 Q3 | 701.48 Thousand CAD | 8.49% |
| 2020 FY | 2.59 Million CAD | 58.81% |
| 2020 Q3 | 618.98 Thousand CAD | 14.0% |
| 2020 Q2 | 542.99 Thousand CAD | -6.29% |
| 2020 Q1 | 579.45 Thousand CAD | 8.21% |
| 2020 Q4 | 851.18 Thousand CAD | 37.51% |
| 2019 Q2 | 397.26 Thousand CAD | 20.75% |
| 2019 FY | 1.63 Million CAD | 15.76% |
| 2019 Q3 | 370.79 Thousand CAD | -6.66% |
| 2019 Q1 | 328.99 Thousand CAD | 38.68% |
| 2019 Q4 | 535.46 Thousand CAD | 44.41% |
| 2018 Q4 | 237.22 Thousand CAD | -43.54% |
| 2018 FY | 1.41 Million CAD | 23.77% |
| 2018 Q2 | 377.85 Thousand CAD | 0.76% |
| 2018 Q3 | 420.15 Thousand CAD | 11.2% |
| 2018 Q1 | 375 Thousand CAD | 1.71% |
| 2017 Q1 | 293 Thousand CAD | 75.55% |
| 2017 FY | 1.13 Million CAD | 62.4% |
| 2017 Q4 | 368.68 Thousand CAD | 26.63% |
| 2017 Q3 | 291.15 Thousand CAD | 56.04% |
| 2017 Q2 | 186.58 Thousand CAD | -36.32% |
| 2016 Q1 | 116.08 Thousand CAD | 0.0% |
| 2016 FY | 701.63 Thousand CAD | 908.54% |
| 2016 Q2 | 118.1 Thousand CAD | 1.74% |
| 2016 Q4 | 166.9 Thousand CAD | -44.47% |
| 2016 Q3 | 300.54 Thousand CAD | 154.49% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 FY | -86.77 Thousand CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| CanadaBis Capital Inc. | 11.78 Million CAD | 99.953% |
| Decibel Cannabis Company Inc. | 41.85 Million CAD | 99.987% |
| Delivra Health Brands Inc. | 6.39 Million CAD | 99.914% |
| Entourage Health Corp. | 3.7 Million CAD | 99.852% |
| Lifeist Wellness Inc. | 5.34 Million CAD | 99.897% |
| Cannara Biotech Inc. | 27.23 Million CAD | 99.98% |
| Medicure Inc. | 13.98 Million CAD | 99.961% |
| PharmaCielo Ltd. | -1.36 Million CAD | 100.402% |
| Rubicon Organics Inc. | 13.14 Million CAD | 99.958% |
| BioSyent Inc. | 25.14 Million CAD | 99.978% |
| Voyageur Pharmaceuticals Ltd. | -2185.00 CAD | 351.67% |